After raising more than $142 million in venture capital earlier this year to support its liver transplant technology, OrganOx is adding a zero to the total with a new acquisition offer fr | The deal ...

Amid a frozen over IPO landscape, LB Pharmaceuticals has filed to go public to fund a pivotal schizophrenia study for its ...

With the FDA’s go-ahead, Coya plans to launch a multicenter phase 2 trial of COYA 302 in patients with ALS, CEO Arun ...

The candidates are sourced from Arnatar’s next-gen RNA discovery engine, dubbed DARGER for dual-functional antisense RNA for ...

At AbbVie, bretisilocin will slot into a well-established neuroscience unit. AbbVie has deals with Gedeon Richter, the source ...

PDS Biotech has reported final phase 2 data on PDS0101 in the tough-to-treat head and neck cancer setting, linking a combination of the immunotherapy and Keytruda to median overall survival (OS) of 39 ...

Tempus AI has acquired the digital pathology developer Paige, including its FDA-cleared, artificial intelligence-powered ...

The Supreme Court is allowing the Trump administration to axe $783 million in federal research funding, reversing a lower ...

Thermo Fisher Scientific cut the ribbon to open a highly automated manufacturing plant in North Carolina—featuring a ...

Arena BioWorks has laid off 30% of its workers 19 months after launching with $500 million and visions of bringing the Bell ...

The Cleveland Clinic's Nathan Pennell, M.D., Ph.D., is switching to the Big Pharma realm to head up hematology and oncology ...

Lighthouse Pharmaceuticals’ plan to become a beacon of hope for Alzheimer’s disease patients has received almost $50 million ...